EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-world evidence on the CamAPS FX hybrid closed-loop system in people living with type 1 diabetes

Charlotte K. Boughton, Tomas Hovorka, Malgorzata E. Wilinska, Sara Hartnell, Roman Hovorka

Metabologia · 2026

DOI: 10.1007/s44357-025-00002-2 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background We analysed real-world data to evaluate the performance of the CamAPS FX hybrid closed-loop system I people living with type 1 diabetes. Methods Users from 19 countries across different age groups who used the system between 1 January 2024, and 31 December 2024, and who had ≥ 60 days of continuous glucose monitor data with ≥ 30% of closed-loop usage were included in the current analysis ( N = 35,714). Results Time in target glucose range (3.9–10 mmol/l) was median (IQR) 69.6% (61.3–77.2) for all users and varied across the different age groups from 62.5% (53.4–71.2) for young adult users aged 18–22 years old to 76.1% (68.9–82.4) for users aged ≥ 65 years. Median (IQR) time spent in hypoglycaemia (< 3.9 mmol/l) was 2.5% (1.4–3.9) overall, and was < 4% across all age groups. Mean glucose and glucose management indicator overall were 8.7 ± 1.2 mmol/l and 7.1 ± 0.5% (53.6 ± 5.8 mmol/mol), respectively. Median (IQR) time in closed-loop was high at 95.7% (92.9‒97.3). Conclusions This retrospective observational analysis of real-world data demonstrates the performance of the CamAPS FX hybrid closed-loop system with outcomes comparable to those reported from previous randomised controlled studies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →